# An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

> **NCT04717414** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Celgene** · enrollment: 313 (actual)

## Conditions studied

- Myeloproliferative Disorders
- Myelofibrosis
- Primary Myelofibrosis
- Post-Polycythemia Vera Myelofibrosis
- Anemia

## Interventions

- **DRUG:** ACE-536
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04717414
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-25
- **Primary completion:** 2025-05-26
- **Final completion:** 2032-08-18
- **Target enrollment:** 313 (ACTUAL)
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04717414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04717414, "An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04717414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*